Navigation Links
GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT(TM)
Date:10/5/2009

PHILADELPHIA, Oct. 5 /PRNewswire/ -- GlaxoSmithKline [NYSE: GSK] today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in support of the approval of VOTRIENT(TM) (pazopanib). Specifically, the panel voted that the benefit-to-risk profile is acceptable for patients with advanced renal cell carcinoma (RCC). Pazopanib is an investigational, oral treatment for patients with advanced RCC.

"Kidney cancer is a very serious disease therefore the committee's recommendation in support of pazopanib is an important step towards bringing a new, oral treatment option to advanced renal cell cancer patients," said Rafael Amado, MD, Vice President, GlaxoSmithKline Oncology R&D Unit. "We look forward to working with the FDA towards the approval of pazopanib."

RCC is the most common type of kidney cancer and accounts for approximately nine out of ten cases. It is estimated that approximately 57,700 people will be diagnosed with kidney cancer and 13,000 people will die from kidney cancer in the United States in 2009. In 2002, an estimated 208,000 new cases of kidney cancer were diagnosed globally.

The advisory committee made its decision based on Phase III pivotal trial data that were presented at the American Society of Clinical Oncology 2009 annual meeting.

About pazopanib

Pazopanib is an investigational medicine that may prevent the growth of new blood vessels to tumors, a process known as angiogenesis. All solid tumors need blood vessels to survive, and medicines in this category may halt the progression of tumor growth.

About pazopanib and clinical development

In its pivotal study, pazopanib was administered orally, once daily. Pazopanib has a broad clinical program across multiple tumor types, with study details available at www.clinicaltrials.gov. Mo
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
2. FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSKs Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
3. FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmabs ARZERRA(TM) (ofatumumab)
4. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
5. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
6. Biotica Strikes Significant Collaboration Deal With GlaxoSmithKline
7. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
8. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
9. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
10. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
11. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Fla. , Aug. 3, 2015  Charleston ... initiation of its second clinical development program with ... candidate, CL-H1T.  CL-H1T contains fast-dissolving ... being developed as a treatment for migraine headache ... "Many patients with migraine headaches also ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
(Date:8/3/2015)... Israel , August 3, 2015 ... it received the statistical analysis of results from a study ... the BVX-005 phase II trial which took place in 2012, ... not exist at the time of the study- in particular ... the epidemic in the United States ...
Breaking Medicine Technology:Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3
... SCOTTSDALE, Ariz. and WASHINGTON, June 15, 2011 The ... and CAQH CORE ® (Committee on Operating Rules ... collaborate on activities related to harmonizing electronic data interchange ... NCPDP and CAQH CORE began exploring the ...
... Endologix, Inc. (Nasdaq: ELGX ), developer and ... today that it has received U.S. Food and Drug ... AFX™ Endovascular AAA System, for the treatment of abdominal ... Annual Meeting of the Society for Vascular Surgery (SVS), ...
Cached Medicine Technology:NCPDP and CAQH CORE Partner on Harmonizing Operating Rules and Standards Across Healthcare 2NCPDP and CAQH CORE Partner on Harmonizing Operating Rules and Standards Across Healthcare 3Endologix Announces FDA Approval of AFX™ Endovascular AAA System 2Endologix Announces FDA Approval of AFX™ Endovascular AAA System 3
(Date:8/3/2015)... ... August 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a ... to present at the Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am ... subsequent archived replay of the Company’s presentation may be accessed via the investor relations ...
(Date:8/3/2015)... ... August 03, 2015 , ... It’s 25 ... Lava Springs, California’s northernmost and among its least visited State Parks. The volcanic ... whose main outflow is at Ahjumawi Lava Springs, part of the Fall River ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 9 article from ... rooms in recent years, according to the American Dental Association. According to a study ... visits went from 1.1 million in a single year to 2.2 million a year. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... decline by 39 percent, according to market research compiled for the National Association ... the U.S. Department of Labor, Bureau of Labor Statistics. As the number of ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dignity Health named Dr. Norris A. Baldwin, ... Room – Gilbert, opening in August. The new facility is licensed under ... Valley. , “Dr. Baldwin is an excellent leader and will ensure our new ...
Breaking Medicine News(10 mins):Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3
... DEXTER, Mich., Oct. 16 ReCellular, Inc., ... used wireless phones and,accessories, today announced it ... Cellular ( http://www.consumercellular.com ), one of,the nation,s ... to,collect wireless handsets for recycling from their ...
... 16 HLTH Corporation,(Nasdaq: HLTH ) today announced ... ended September 30, 2007 at approximately 4:00 pm (ET) ... announced, HLTH Corporation,s 84% owned,subsidiary, WebMD Health Corp. (Nasdaq: ... financial results for the three months ended September 30,2007 ...
... Pharmaceuticals,Corporation (NASDAQ: ASPV ; TSX: ASV) today ... $62 million for the third,quarter of 2007 compared ... quarter,of 2006. As previously announced, Aspreva will ... 2007. The Company will hold a conference,call and ...
... from yogurt(TM) in an easy-to-swallow caplet., VANCOUVER, ... launch of AccuFlora Pro-Biotic Acidophilus, a combination of,five ... and,supports a healthy immune system with the good ... to MayoClinic.com, there is growing public and scientific,interest ...
... of G&D, Dr. Michael Cleary (Stanford University School of ... critical player in the establishment of leukemia stem cells, ... leukemia (MLL) is a distinctive type of leukemia ... by the presence of a break and rearrangement of ...
... CHICAGO, Oct. 16 The Cambridge Group, a ... Carrie Shea,principals of the firm. Mr. Miller ... and,industry experience to The Cambridge Group. In his ... improvements in senior,executive and consulting positions. In his ...
Cached Medicine News:Health News:ReCellular Named Exclusive Cell Phone Recycling Partner for Consumer Cellular 2Health News:ReCellular Named Exclusive Cell Phone Recycling Partner for Consumer Cellular 3Health News:HLTH Corporation Announces Third Quarter Earnings Release Date and Conference Call 2Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 2Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 3Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 4Health News:Northwest Natural Products Introduces AccuFlora(R) 2Health News:The Cambridge Group Names Two New Principals 2
... Designed To Be Used With The Gills ... On The Cornea For Making Limbal Relaxing Incisions., ... The Gills Nomograms. 6mm & 8mm Chord Length ... Relaxing Incisions.5mm Inner Circle Assists In Sizing A ...
... This System Is Designed To Manually Dilate ... Efficacy. The Bimanual Technique Maximizes Safety By ... Parallel, Rather Than Perpendicular, To The Plane ... Risk Of Inadvertent Capsule Tears. Pupil Stretching ...
... To Rest Either Nasally Or Temporally ... Allowing Eyelids To Be Opened From ... Possible Aperture., ,Open And Close With ... To The Globe During Clear Corneal ...
... Unique Reversible Speculums Designed To Rest ... Flipping The Speculums Over, Allowing Eyelids ... Fissures To The Widest Possible Aperture.,Open ... Unobstructed Around-The-Clock Access To The Globe ...
Medicine Products: